Market News AIOpen the app

BioVie shared new data showing how Long COVID patients might respond differently to treatment with bezisterim.

TrialRead the original at globenewswire.com
Good for BIVI

BioVie reported that two biomarker groups improved in different symptoms during bezisterim treatment. This supports the drug's promise, though the Phase 2 findings and proposed cause remain early evidence.

BIVI · BioVie Inc.

AI read · Good for BIVI

The AI's read

The findings give BioVie evidence that bezisterim may help different groups of people with Long COVID in different ways. The reported improvements support further study, but the trial is Phase 2 and the proposed cause remains a hypothesis.

Get alerts for BIVI

Follow BioVie Inc. (BIVI) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BIVI
Free on the App Store and Google Play, or on the web.